Filtered By:
Source: Circulation
Drug: Coumadin

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 47 results found since Jan 2013.

Response to letter regarding article, "warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis".
PMID: 25539527 [PubMed - in process]
Source: Circulation - December 23, 2014 Category: Cardiology Authors: Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L Tags: Circulation Source Type: research

Letter by qureshi et Al regarding article, "warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis".
PMID: 25539526 [PubMed - in process]
Source: Circulation - December 23, 2014 Category: Cardiology Authors: Qureshi W, Alirhayim Z, Khalid F Tags: Circulation Source Type: research

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation.
CONCLUSIONS: -In general practice settings, dabigatran was associated with reduced risk of ischemic stroke, intracranial hemorrhage, and death, and increased risk of major gastrointestinal hemorrhage compared with warfarin in elderly patients with non-valvular AF. These associations were most pronounced in patients treated with dabigatran 150 mg twice daily, whereas the association of 75 mg twice daily with study outcomes was indistinguishable from warfarin except for a lower risk of intracranial hemorrhage with dabigatran. PMID: 25359164 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2014 Category: Cardiology Authors: Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA Tags: Circulation Source Type: research

Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.
CONCLUSIONS: -GDF-15 is a risk factor for major bleeding, mortality and stroke in atrial fibrillation. The prognostic value for major bleeding and death remained even in the presence of NT-proBNP and hs-TnI. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT00412984. PMID: 25294786 [PubMed - as supplied by publisher]
Source: Circulation - October 7, 2014 Category: Cardiology Authors: Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, on behalf of the ARISTOTLE Investigators Tags: Circulation Source Type: research

Efficacy and Safety of Rivaroxaban Compared with Warfarin among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET AF Trial.
CONCLUSIONS: -Elderly patients had higher stroke and major bleeding rates than younger patients, but the efficacy and safety of rivaroxaban relative to warfarin did not differ with age, supporting rivaroxaban as an alternative for the elderly. Clinical Trial Registration Information-ClinicalTrials.gov; Unique Identifier: NCT00403767. PMID: 24895454 [PubMed - as supplied by publisher]
Source: Circulation - June 3, 2014 Category: Cardiology Authors: Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, on behalf of the ROCKET AF Steering Committee and Investigators Tags: Circulation Source Type: research

Periprocedural Stroke and Bleeding Complications in Patients undergoing Catheter Ablation of Atrial Fibrillation with Different Anticoagulation Management: Results from the "COMPARE" Randomized Trial.
CONCLUSIONS: This is the first randomized study showing that performing catheter ablation of AF without warfarin discontinuation reduces the occurrence of peri-procedural stroke and minor bleeding complications when compared to bridging with low molecular weight heparin. CLINICAL TRIAL REGISTRATION INFORMATION: www.clinicaltrials.gov/. Identifier: NCT01006876. PMID: 24744272 [PubMed - as supplied by publisher]
Source: Circulation - April 17, 2014 Category: Cardiology Authors: Di Biase L, Burkhardt D, Santangeli P, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Bai R, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Rus Tags: Circulation Source Type: research

Comparing the Imperfect with the Imperfect: The Imprecise Science of Assessing the Risk and Benefits of Anticoagulation in Atrial Fibrillation.
Abstract Atrial Fibrillation (AF) is the most common arrhythmia in the United States, with approximately 7 million Americans estimated to have AF by 2020.(1,2) A major cause for morbidity and mortality in AF is stroke. Pharmacologic therapy for the prevention of stroke has undergone a renaissance with the advent of newer oral anticoagulants (NOACs) that are safe and effective alternatives to warfarin. However, the decision to initiate anticoagulation remains a subjective assessment of risks versus benefits. Although guided by well-validated risk scores for stroke and bleeding,(3,4,5) real world decisions on antico...
Source: Circulation - March 29, 2014 Category: Cardiology Authors: Ellenbogen KA, Tan AY Tags: Circulation Source Type: research

Outcomes of Temporary Interruption of Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF.
CONCLUSIONS: TI of oral anticoagulation is common and associated with substantial stroke risks and bleeding risks that were similar among patients treated with rivaroxaban or warfarin. Further investigation is needed to determine the optimal management strategy in AF patients requiring TI of anticoagulation. CLINICAL TRIAL REGISTRATION INFORMATION: www.ClinicalTrials.gov. Identifier: NCT00403767. PMID: 24552831 [PubMed - as supplied by publisher]
Source: Circulation - February 19, 2014 Category: Cardiology Authors: Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC, on behalf of the ROCKET AF Investigators Tags: Circulation Source Type: research

A National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation.
CONCLUSIONS: This study demonstrates widespread suboptimal anticoagulation control, suggesting an urgent need to improve oral anticoagulation care for most patient segments in the United States. PMID: 24493817 [PubMed - as supplied by publisher]
Source: Circulation - February 3, 2014 Category: Cardiology Authors: Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, Hylek EM Tags: Circulation Source Type: research

Warfarin Use and the Risk for Stroke and Bleeding in Patients with Atrial Fibrillation Undergoing Dialysis.
CONCLUSIONS: Our results suggest that warfarin use is not beneficial in reducing stroke risk but is associated with a higher bleeding risk in patients with AF undergoing dialysis. PMID: 24452752 [PubMed - as supplied by publisher]
Source: Circulation - January 22, 2014 Category: Cardiology Authors: Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L Tags: Circulation Source Type: research

Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis.
CONCLUSIONS: The efficacy of both dosages of dabigatran was consistent with the overall trial irrespective of renal function. However, with the CKD-EPI and MDRD equations both dabigatran doses displayed significantly lower rates of major bleeding in patients with GFR ≥80 ml/min. CLINICAL TRIAL REGISTRATION INFORMATION: www.clinicaltrials.gov. Identifier: NCT00262600. PMID: 24323795 [PubMed - as supplied by publisher]
Source: Circulation - December 9, 2013 Category: Cardiology Authors: Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L Tags: Circulation Source Type: research

Causes of Death and Influencing Factors in Patients with Atrial Fibrillation: A Competing Risk Analysis from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study.
CONCLUSIONS: The majority of deaths are not related to stroke in a contemporary anticoagulated AF population. These results emphasize the need to identify interventions beyond effective anticoagulation, in order to further reduce mortality in AF. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov. Identifier: NCT00262600. PMID: 24016454 [PubMed - as supplied by publisher]
Source: Circulation - September 9, 2013 Category: Cardiology Authors: Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom JW, Themeles E, Ezekowitz MD, Wallentin L, Yusuf S Tags: Circulation Source Type: research

Stroke or Transient Ischemic Attack in Patients with Transvenous Pacemaker or Defibrillator and Echocardiographically Detected Patent Foramen Ovale.
CONCLUSIONS: In patients with endocardial leads, the presence of a PFO on routine echocardiography is associated with a substantially increased risk of embolic stroke/TIA. This finding suggests a role of screening for PFOs in patients who require CIEDs, if detected, PFO closure, anticoagulation, or non-vascular lead placement may be considered. PMID: 23946264 [PubMed - as supplied by publisher]
Source: Circulation - August 14, 2013 Category: Cardiology Authors: Desimone CV, Friedman PA, Noheria A, Patel NA, Desimone DC, Bdeir S, Aakre CA, Vaidya VR, Slusser JP, Hodge DO, Ackerman MJ, Rabinstein AA, Asirvatham SJ Tags: Circulation Source Type: research

Antithrombotic Therapy for Patients with Atrial Fibrillation and Atherothrombotic Vascular Disease: Striking the Right Balance between Efficacy and Safety.
Abstract Atrial fibrillation (AF), the most prevalent cardiac arrhythmia, is estimated to affect 1.5 to 2.0% of the general population, i.e., at least 100 million people worldwide.(1) Left untreated, patients with nonvalvular AF (NVAF) are exposed to an annual risk of thromboembolic stroke of approximately 5%, resulting in 5 million AF-related strokes each year.(1) Properly dosed anticoagulation (e.g., warfarin adjusted to an international normalized ratio [INR] of 2.0 to 3.0) is extremely effective in preventing AF-related strokes, reducing risk by two-thirds compared with no therapy, and by one-half compared to ...
Source: Circulation - July 16, 2013 Category: Cardiology Authors: Patrono C, Andreotti F Tags: Circulation Source Type: research

New Oral Anticoagulants in Atrial Fibrillation Forever?
Abstract Atrial fibrillation is the most common chronic cardiac arrhythmia in clinical cardiology. It affects about 1% of the population, and of individuals over the age of 80 about 10% have this rhythm disturbance. Due to the loss of the atrial contribution to ventricular filling, left ventricular function is diminished resulting in a propensity to heart failure, fatigue and disability. Furthermore, the sensation of palpations can be very disturbing for younger patients and may hamper them in their physical and professional activities. Finally, the diminished blood flow through the heart, especially the left atri...
Source: Circulation - June 14, 2013 Category: Cardiology Authors: Verheugt FW Tags: Circulation Source Type: research